In Vivo is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

Brought to you by

Watson buys Specifar for €400mm to expand into Greece

Executive Summary

Strengthening its position in important European countries, Watson Pharmaceuticals Inc. (generics and branded women’s health products) has acquired private generic drug manufacturer Specifar Pharmaceuticals SA for €400mm ($562mm) in cash. Specifar stockholders may also receive up to €40mm in earn-outs related to the first five years of profits for the company’s generic proton pump inhibitor esomeprazole (AstraZeneca’s Nexium), which is awaiting approval and should be launched later this year in key European markets. The earn-outs will be based on sales in major territories in Europe, Asia, Latin America, and Canada.
Deal Industry
  • Pharmaceuticals
  • Pharmaceuticals
    • Generic Drugs
Deal Status
  • Final
Deal Type
  • Acquisition
    • Full Acquisition
    • Includes Contract
    • Includes Earnout
    • Payment Includes Cash

Related Companies